With Pandemic in Rearview Mirror, BriaCell Charges Ahead with Cancer Immunotherapy

Published on :

With Pandemic in Rearview Mirror, BriaCell Charges Ahead with Cancer Immunotherapy By Mark TerryApril 25, 2023 Many biopharma companies had to place their clinical trials on hold during the first [….]

BlueSphere Bio Aims for Next-Level Personalized Cancer Cell Therapy

Headshot of David Apelian
Published on :

Chimeric Antigen Receptor T cell (CAR-T) therapies, such as those developed by Kite Pharma, have revolutionized the approach to treating hematological cancers, but the therapies have limitations due to toxicity concerns. Pennsylvania-based BlueSphere Bio believes its approach through the use of TCR-T cell therapies will provide a more precise treatment option for patients.

Three New Members with Ties to Johns Hopkins Appointed to National Cancer Advisory Board by President Biden

Published on :

WASHINGTON – Today, President Biden announced the appointment of seven distinguished clinicians and researchers to the National Cancer Advisory Board, which plays an important role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program. President Biden is committed to ending cancer as we know it – including by making sure his Administration is investing in research and development that will help advance breakthroughs to prevent, detect, and treat diseases like cancer. The National Cancer Advisory Board will compliment the Administration’s efforts to build on the spirit and learnings of the Cancer Moonshot, which President Biden led in the Obama-Biden Administration.

Ascentage Pharma and Innovent Biologics Reach Multifaceted Strategic Agreement Totaling $245M

Published on :

Ascentage Pharma (6855.HK), a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Innovent Biologics (1801.HK, “Innovent”), today announced a multifaceted strategic collaboration.

Gaithersburg’s miRecule Inc. closes $5.7M to Create Breakthrough RNA Therapies for Cancer and Muscular Dystrophy

Published on :

miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced today it has closed over $5.7M in seed funding. The funding round was led by Alexandria Venture Investments, along with Boutique Venture Partners, Pathway Bioventures, Alumni Ventures Group, and national angel investors, with additional funding coming from the Maryland Momentum Fund and the FSHD Society. This funding includes a non-dilutive $2M Phase II SBIR grant from the National Cancer Institute.

WindMIL Therapeutics Appoints Dr. Kimberly Noonan as Chief Science & Technology Officer

Published on :

WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs®) for cancer immunotherapy, today announced the appointment of Co-Founder Kimberly Noonan, PhD, MPH, to Executive Vice President, Chief Science & Technology Officer. In this role, Dr. Noonan’s leadership will expand to include WindMIL’s efforts in manufacturing and manufacturing science and technology (MS&T).

Immunomic Therapeutics Announces License Agreement With Lineage Cell Therapeutics for Cancer Immunotherapy

Published on :

Partnership Leverages Lineage’s Investigational VAC Allogeneic Cancer Vaccine Platform and Immunomic’s Proprietary Tumor Associated Antigen to Generate a Novel Oncology Product Candidate